How much funding has Beacon Biosignals raised?

Beacon Biosignals has raised $116.0M in total funding, most recently a Series B round.

Who are Beacon Biosignals's investors?

Beacon Biosignals's investors include General Catalyst, Innoviva, Section 32, Casdin Capital, GV, Nexus NeuroTech Ventures.

When was Beacon Biosignals founded?

Beacon Biosignals was founded in 2019.

Where is Beacon Biosignals headquartered?

Beacon Biosignals is headquartered in Boston, United States.

What industry is Beacon Biosignals in?

Beacon Biosignals operates in Artificial Intelligence, Biotech, Healthcare, Medical Devices.

How many employees does Beacon Biosignals have?

Beacon Biosignals has 51-200 employees.

Beacon Biosignals

Making brain function measurable and actionable at scale

Boston, United States · Founded 2019 · $116.0M raised

Artificial Intelligence

Biotech

Healthcare

Medical Devices

Headquarters: Boston
Employees: 51–200
Founded: 2019
Business Model: B2B

Website: beacon.bio
Total Funding: $116.0M
Last Round: $86.0M Series BNov 2025
Rounds: 3

About

Beacon Biosignals is a neurotechnology company using AI-powered EEG analytics to accelerate drug development for neurological and psychiatric disorders. Its platform analyzes real-world brain data from clinical trials, helping biopharma companies measure treatment efficacy and identify biomarkers across epilepsy, sleep disorders, and other conditions.

Summary

Beacon Biosignals is an Artificial Intelligence company based in Boston, United States, founded in 2019. It has raised $116.0M in total across 3 rounds, most recently a $86.0M Series B round in Nov 2025. Investors include General Catalyst, Innoviva and Section 32.

LinkedIn X (Twitter)